Skip to main content

Mirati Therapeutics, Inc.

MRTXDelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001576263

Mirati Therapeutics, Inc. was delisted in 2024; its insiders filed their last Form 4 on Jan 25, 2024; 218 institutions reported holding it in 13F filings for Q4 2023, worth $5.03B in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Mirati Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Mirati Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Mirati Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Lewis JosephOther: See remarks0IndirectJan 25, 20240
Fuglesang ChristopherOther: See remarks0IndirectJan 25, 20240
Boxer Asset Management Inc.Other: See remarks0IndirectJan 25, 20240
Boxer Capital, LLCOther: See remarks0IndirectJan 25, 20240
Davis Aaron I.Other: See remarks0IndirectJan 25, 20240
MVA Investors, LLCOther: See remarks0IndirectJan 25, 20240
Braslyn Ltd.Other: See remarks0IndirectJan 25, 20240
Dissanayake Shehan BharathaOther: See remarks0IndirectJan 25, 20240
Lockend Five, LLCOther: See remarks0IndirectJan 25, 20240
Carter Bruce L ADirector0Jan 23, 20240
Gallagher Carol GiltnerDirector0Jan 23, 20240
Hasnain FaheemDirector0Jan 23, 20240
Johnson Craig ADirector0Jan 23, 20240
Sharp ShaliniDirector0Jan 23, 20240
Moriarty John BChief Legal Officer0Jan 23, 20240
Baum Charles MFounder, President, and CEO0Jan 23, 20240
Christensen JamieEVP & Chief Scientific Officer0Jan 23, 20240
Hickey BenjaminEVP, Chief Commercial Officer0Jan 23, 20240
Martinez Maria EDirector0Jan 23, 20240
Cherrington Julie MDirector0Jan 23, 20240
Sandler Alan B.Chief Medical Officer0Jan 23, 20240
Ondrey AaronChief Financial Officer0Jan 23, 20240
Stelzer LaurieChief Financial Officer102,312Aug 10, 20230
Fuchs Henry JDirector10,465Jan 24, 20230
Meek David D.Chief Executive Officer151,171Jan 24, 20230
Reed Vickie SSVP, Chief Accounting Officer15,369Jan 18, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 18, 2024 (view filing)Jan 162 daysHickey BenjaminEVP, Chief Commercial OfficerSSale−1.60K$59.02−$94.3K−1.3%117.0K after2 lots
Jan 18, 2024 (view filing)Jan 162 daysChristensen JamieEVP & Chief Scientific OfficerSSale−1.60K$59.02−$94.3K−1.0%155.9K after2 lots
Jan 9, 2024 (view filing)Jan 81 dayHickey BenjaminEVP, Chief Commercial OfficerSSale−2.09K$58.92−$123.1K−1.7%118.6K after
Jan 5, 2024 (view filing)Jan 41 dayChristensen JamieEVP & Chief Scientific OfficerSSale−1.53K$58.81−$90.0K−1.0%157.1K after
Dec 19, 2023 (view filing)Dec 181 dayChristensen JamieEVP & Chief Scientific OfficerSSale−2.39K$57.50−$137.3K−1.7%141.6K after
Dec 14, 2023 (view filing)Dec 131 dayHickey BenjaminEVP, Chief Commercial OfficerSSale−2.22K$56.67−$125.8K−2.1%103.7K after
Sep 12, 2023 (view filing)Sep 84 daysChristensen JamieEVP & Chief Scientific OfficerSSale−2.39K$35.63−$85.1K−1.6%144.0K after
Aug 15, 2023 (view filing)9:39 PM ETAug 114 daysLewis Joseph and 6 othersOther: See remarksPPurchase+57.5K$27.80+$1.60M+25.0%287.9K afterDuplicate filing
Aug 15, 2023 (view filing)9:39 PM ETAug 114 daysLewis Joseph and 6 othersOther: See remarksPPurchase+1.20M$27.80+$33.4M+60.1%3.20M afterDuplicate filing
Aug 15, 2023 (view filing)9:38 PM ETAug 114 daysLewis Joseph and 6 othersOther: See remarksPPurchase+57.5K$27.80+$1.60M+25.0%287.9K after
Aug 15, 2023 (view filing)9:38 PM ETAug 114 daysLewis Joseph and 6 othersOther: See remarksPPurchase+1.20M$27.80+$33.4M+60.1%3.20M after
Aug 14, 2023 (view filing)Aug 113 daysHasnain FaheemDirectorPPurchase+10.8K$27.80+$300.0KNew position10.8K after
Jun 2, 2023 (view filing)Jun 2Same dayStelzer LaurieChief Financial OfficerSSale−4.65K$37.06−$172.2K−5.5%80.0K after
May 24, 2023 (view filing)May 24Same dayChristensen JamieEVP & Chief Scientific OfficerSSale−619$45.29−$28.0K−0.5%124.1K after
Jan 20, 2023 (view filing)Jan 182 daysCherrington Julie MDirectorSSale−2.55K$44.66−$113.7K−100.0%0 after
Jan 19, 2023 (view filing)Jan 172 daysMeek David D.Chief Executive OfficerSSale−3.18K$42.38−$134.7K−4.9%61.8K after
Jan 19, 2023 (view filing)Jan 172 daysChristensen JamieEVP, Chief Scientific OfficerSSale−2.25K$42.38−$95.1K−2.2%97.9K after2 lots
Jan 19, 2023 (view filing)Jan 172 daysHickey BenjaminEVP, Chief Commercial OfficerSSale−1.57K$42.38−$66.4K−3.2%47.2K after2 lots
Jan 10, 2023 (view filing)Jan 91 dayHickey BenjaminEVP, Chief Commercial OfficerSSale−2.09K$45.37−$94.7K−4.1%48.8K after
Jan 5, 2023 (view filing)Jan 41 dayBaum Charles MPresident,Founder,Head of R&DSSale−3.65K$46.60−$170.0K−2.1%168.8K after
Jan 5, 2023 (view filing)Jan 41 dayChristensen JamieEVP, Chief Scientific OfficerSSale−1.95K$46.60−$90.8K−1.9%100.1K after
Dec 21, 2022 (view filing)Dec 21Same dayBaum Charles MPresident,Founder,Head of R&DSSale−9.09K$40.42−$367.5K−5.0%172.4K after
Dec 21, 2022 (view filing)Dec 21Same dayHickey BenjaminEVP, Chief Commercial OfficerSSale−3.25K$40.41−$131.3K−6.0%50.9K after
Dec 21, 2022 (view filing)Dec 21Same dayMeek David D.Chief Executive OfficerSSale−4.62K$40.41−$186.5K−6.6%65.0K after
Dec 20, 2022 (view filing)Dec 164 daysChristensen JamieEVP, Chief Scientific OfficerSSale−2.41K$43.00−$103.6K−2.3%102.1K after
Dec 5, 2022 (view filing)Dec 23 daysChristensen JamieEVP, Chief Scientific OfficerSSale−1.73K$90.19−$155.7K−1.6%104.5K after
Nov 28, 2022 (view filing)Nov 28Same dayBaum Charles MPresident,Founder,Head of R&DSSale−69.3K$100.00−$6.93M−35.1%127.9K after
Aug 16, 2022 (view filing)Aug 124 daysCarter Bruce L ADirectorSSale−10.0K$85.49−$854.9K−62.4%6.02K after2 lots
Jun 14, 2022 (view filing)May 2322 daysLateChristensen JamieEVP, Chief Scientific OfficerSSale−624$63.54−$39.6K−0.7%86.8K after
Feb 14, 2022 (view filing)Feb 113 daysFuchs Henry JDirectorSSale−11.0K$105.61−$1.16M−64.6%6.02K after3 lots
Jan 20, 2022 (view filing)Jan 191 dayCherrington Julie MDirectorSSale−1.48K$116.07−$171.2K−36.7%2.55K after
Jan 18, 2022 (view filing)Jan 18Same dayReed Vickie SSVP, Chief Accounting OfficerSSale−533$120.48−$64.2K−3.4%15.4K after
Jan 18, 2022 (view filing)Jan 18Same dayChristensen JamieEVP, Chief Scientific OfficerSSale−627$120.51−$75.6K−0.7%87.4K after
Jan 18, 2022 (view filing)Jan 18Same dayBaum Charles MPresident,Founder,Head of R&DSSale−2.52K$120.48−$303.2K−1.9%127.9K after
Jan 18, 2022 (view filing)Jan 18Same dayHickey BenjaminEVP, Chief Commercial OfficerSSale−627$120.48−$75.5K−1.8%35.0K after
Jan 7, 2022 (view filing)Jan 7Same dayHickey BenjaminEVP, Chief Commercial OfficerSSale−1.96K$135.94−$267.0K−7.3%24.8K after
Jan 7, 2022 (view filing)Jan 7Same dayReed Vickie SSVP, Chief Accounting OfficerSSale−345$135.94−$46.9K−3.2%10.5K after
Jan 6, 2022 (view filing)Jan 42 daysBaum Charles MPresident,Founder,Head of R&DSSale−4.11K$147.75−$607.9K−3.9%101.2K after2 lots
Jan 6, 2022 (view filing)Jan 42 daysChristensen JamieEVP, Chief Scientific OfficerSSale−1.44K$147.72−$213.0K−1.8%77.3K after
Jan 6, 2022 (view filing)Jan 42 daysReed Vickie SSVP, Chief Accounting OfficerSSale−758$147.74−$112.0K−6.5%10.9K after
Dec 7, 2021 (view filing)Dec 61 dayChristensen JamieEVP, Chief Scientific OfficerSSale−1.20K$130.79−$157.1K−2.0%59.5K after2 lots
Dec 3, 2021 (view filing)Dec 3Same dayBaum Charles MPresident & Head of R&DSSale−47.2K$133.20−$6.29M−29.5%112.7K after7 lots